Expression of lncRNA UCA1 in ovarian cancer and its clinical significance

Objectives: To explore the expression and clinical significance of lncRNA-UCA1 in ovarian cancer. Materials and Methods: The expression of lncRNA-UCA1 in 26 ovarian cancer tissue and 16 normal and benign ovarian tissue were detected using qRT-PCR method, and the correlation of expression level with clinicopathological features were analyzed. Results: Higher lncRNA-UCA1 expression level were detected in ovarian cancer tissue than those in normal ovarian tissue (p < 0.05). There were significant correlations between higher expression of lncRNA-UCA1 with tumor staging (p = 0.000), histological grades (p = 0.000), peritoneal effusion (p = 0.001), and lymph node metastasis (p = 0.000), but not with age. Conclusion: lncRNA-UCA1 may play a vital role in the metastasis of ovarian cancer and it is expected to be a potential novel biomarker and therapeutic target of ovarian cancer.

ncRNA; UCA1; Ovarian cancer; MACC1; Metastasis.

[1] Lu K.H., Skates S., Hernandez M.A., Bedi D., Bevers T., Leeds L., et al.: “A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value”. Cancer, 2013, 119, 3454.

[2] Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M.: “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008”. Int. J. Cancer, 2010, 127, 2893.

[3] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.

[4] Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al.: “Diagnostic markers for early detection of ovarian cancer”. Clin. Cancer Res., 2008, 14, 1065.

[5] Jemal A., Siegel R., Xu J., Ward E.: “Cancer statistics, 2010”. CA Cancer J. Clin., 2010, 60, 277.

[6] Cannistra S.A.: ‘Cancer of the ovary”. N. Engl. J. Med., 2004, 351, 2519.

[7] Howlader N., Noone A.M., Krapcho M., Garshell J., Neyman N., Altekruse S.F., et al.: “SEER Cancer Statistics Review, 1975-2010”. National Cancer Institute. Bethesda, MD, Available at: http://seer.cancer.gov/csr/1975_2010/

[8] Holschneider C.H., Berek J.S.: “Ovarian cancer: epidemiology,biology, and prognostic factors”. Semin. Surg. Oncol., 2000, 19, 3.

[9] Buys S.S., Partridge E., Black A., Johnson C.C., Lamerato L., Isaacs C., et al.: “Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial'. JAMA, 2011, 305, 2295.

[10] Fung M.F., Bryson P., Johnston M., Chambers A., Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group: “Screening postmenopausal women for ovarian cancer: a systematic review”. J. Obstet. Gynaecol. Can., 2004, 26, 717.

[11] Veneroni R., Peracchio C., Castino R., Isidoro C.: “Patented biomarkers for the early detection of ovarian cancer”. Recent Pat. Biomark., 2011, 1, 1.

[12] Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., et al.: “Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis”. Nature, 2010, 464, 1071.

[13] Ørom U.A., Derrien T., Beringer M., Gumireddy K., Gardini A., Bussotti G., et al.: “Long noncoding RNAs with enhancer-like function in human cells”. Cell, 2010, 143, 46.

[14] Guttman M., Donaghey J., Carey B.W., Garber M., Grenier J.K., Munson G., et al.: “LincRNAs act in the circuitry controlling pluripotency and differentiation”. Nature, 2011, 477, 295.

[15] Lee J.T.: “Epigenetic regulation by long noncoding RNAs”. Science, 2012, 338, 1435.

[16] An S., Song J.J.: “The coded functions of noncoding RNAs for gene regulation”. Mol. Cells, 2011, 31, 491.

[17] Wilusz J.E., Sunwoo H., Spector D.L.: “Long non-coding RNAs: functional surprises from the RNA world”. Genes Dev., 2009, 23, 1494.

[18] Zhao M., Qiu Y., Yang B., Sun L., Hei K., Du X., Li Y.: “Long noncoding RNAs involved in gynecological cancer”. Int. J. Gynecol. Cancer, 2014, 24, 1140.

[19] Hauptman N., Glavac D.: “Long non-coding RNA in cancer”. Int. J. Mol. Sci., 2013, 14, 4655.

[20] Mitra S.A., Mitra A.P., Triche T.J.: “A central role for long noncoding RNA in cancer”. Front. Genet., 2012, 3, 17.

[21] Ponting C.P., Oliver P.L., Reik W.: “Evolution and functions of long noncoding RNAs”. Cell, 2009, 136, 629.

[22] Gutschner T., Diederichs S.: “The hallmarks of cancer: a long non coding RNA point of view”. RNA Biol., 2012, 9, 703.

[23] Gibb E.A., Brown C.J., Lam W.L.: “The functional role of long noncoding RNA in human carcinomas”. Mol. Cancer, 2011, 10, 38.

[24] Jern P., Sperber G.O., Ahlsén G., Blomberg J.: “Sequence variability, gene structure, and expression of full-length human endogenous retrovirus”. J. Virol., 2005, 79, 6325.

[25] Fang Z., Wu L., Wang L., Yang Y., Meng Y., Yang H.: “Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis”. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2014, 117, 89.

[26] Wang Y., Chen W., Yang C., Wu W., Wu S., Qin X., et al.: “Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer”. Int. J. Oncol., 2012, 41, 276.

[27] Rorive S., Sandras F., Biskri L., Fossion C., Catteau X., Roumeguere T., et al.: “RT PCR-based UCA1 expression detection in urine samples as non-invasive reliable method for urothelial cancer diagnosis”. EJC Suppl., 2009, 7, 28.

[28] Liu S.P., Yang J.X., Cao D.Y., Shen K.: “Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials”. Cancer Biol. Med., 2013, 10, 138.

[29] Yang C., Li X., Wang Y., Zhao L.,Chen W.: “Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells”. Gene, 2012, 496, 8.

[30] Wang F., Li X., Xie X., Zhao L., Chen W.: “UCA1, a non-proteincoding RNA up-regulated in bladder carcinoma and embryo, in fluencing cell growth and promoting invasion”. FEBS Lett., 2008, 582, 1919.

[31] Livak K.J., Schmittgen T.D.: “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method”. Methods, 2001, 25, 402.

[32] Wu W., Zhang S., Li X., Xue M., Cao S., Chen W.: “Ets-2 regulates cell apoptosis via the Akt pathway, through the regulation of urothelial cancer associated 1, a long non-coding RNA, in bladder cancer cells”. PLoS One, 2013, 8, e73920.

[33] Fan Y., Shen B., Tan M., Mu X., Qin Y., Zhang F., et al.: “Long noncoding RNA UCA1 increases chemoresistances of bladder cancer cells by regulating Wnt signaling”. FEBS J., 2014, 281, 1750.

[34] Wang F., Zhou J., Xie X., Hu J., Chen L., Hu Q., et al.: “Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells”. Neoplasma, 2015, 62, 432.

[35] Lee J.Y., Kim H.S., Suh D.H., Kim M.K., Chung H.H., Song Y.S.: “Ovarian cancer biomarker discovery based on genomic approaches”. J. Cancer Prev., 2013, 18, 298.